The outlook revision reflects Moody’s Investors Service’s expectation that MedStar’s operations will remain pressured over the coming years.
Moody’s also affirmed the “A2” rating on MedStar’s bonds. The rating affirmation is based on numerous factors, including MedStar’s diversified clinical delivery network, strengthening market position and consistently profitable operations.
More articles on healthcare finance:
New England Baptist inks bundle deal for GE employees’ joint replacements
Medical device company Lensar files for bankruptcy
AMGA sends CMS’ Andy Slavitt MACRA recommendations: 6 things to know
